United States News Todas as matérias

Belden (NYSE:BDC) announced that it has completed its acquisition of RUCKUS Networks, a global provider of intelligent network solutions, from Vistance Networks (NASDAQ:VISN).

CMA CGM Group agreed to acquire FedEx Supply Chain, the contract logistics arm of FedEx (NYSE:FDX), in a $1.4 billion enterprise value deal aimed at expanding its North American logistics footprint through CEVA Logistics.

Firefly Aerospace (NASDAQ:FLY) announced it received a $144 million NASA CLPS contract to deliver an accelerated Blue Ghost lunar lander mission targeted for 2028.

Brand Engagement Network (NASDAQ:BNAI) completed its acquisition of Cataneo on June 30, 2026, adding a profitable enterprise software business with recurring revenue.

President Donald Trump suspended certain duties on phosphate fertilizer imported from Morocco for up to eight months to support U.S. farm supply before the next planting season.

Abivax stock climbed more than 30% after the French biotech released additional data from its late-stage trial of obefazimod, showing that cancer cases in the study were consistent with background rates expected in that patient population.

Toyota (NYSE:TM) and Joby Aviation (NYSE:JOBY) launched the initial phase of a strategic manufacturing alliance, creating a joint venture to advance all-electric air taxi production.

PetMed Express (NASDAQ:PETS) confirmed receipt of an unsolicited, non-binding and conditional proposal from SilverCape Investments to acquire all outstanding shares for $3.00 per share in cash.

ADC Therapeutics SA (NYSE:ADCT) said it has completed enrollment in the LOTIS-7 Phase 1b clinical trial evaluating ZYNLONTA in combination with glofitamab for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

The combined market value of the Magnificent Seven — Microsoft (NASDAQ:MSFT), Nvidia (NASDAQ:NVDA), Alphabet (NASDAQ:GOOGL), Apple (NASDAQ:AAPL), Meta Platforms (NASDAQ:META), Tesla (NASDAQ:TSLA), and Amazon.com (NASDAQ:AMZN) — fell about $2.3 trillion in June, according to CNBC.

ADC Therapeutics (NYSE:ADCT) said it has completed enrollment in the LOTIS-7 Phase 1b clinical trial evaluating ZYNLONTA in combination with glofitamab for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Vistagen (NASDAQ:VTGN) announced topline results from the PALISADE-4 Phase 3 trial of intranasal fasedienol for the acute treatment of social anxiety disorder.

Stoke Therapeutics Inc. (NASDAQ:STOK) said it has completed enrollment of 162 patients in its Phase 3 EMPEROR study of zorevunersen, an investigational RNA medicine for Dravet syndrome.

Air Products (NYSE:APD) announced it will not proceed with the Louisiana Clean Energy Complex, citing expected financial returns not meeting the company’s strict criteria.

FAST TRACK GROUP (NASDAQ:FTRK) reported audited financial results for the fiscal year ended February 28, 2026, showing total revenue of $1.7 million, a 112% increase from the prior year.

Flash Sports & Media Holdings (NASDAQ:FLZH) signed a confidential, non-binding letter of intent to acquire a 51% controlling interest in Dubai-based hospitality group Nooa.

The U.S. Food and Drug Administration selected seven companies for a pilot program designed to accelerate reviews of new domestic pharmaceutical manufacturing facilities.

PowerBank (NASDAQ:PBK) announced that its subsidiary, Abundant Solar Power, has signed an operations and maintenance agreement with Honeywell for a 21 MW portfolio of three New York community solar projects.

Unicycive Therapeutics (NASDAQ:UNCY) said the U.S. Food and Drug Administration issued a Complete Response Letter for its resubmitted new drug application for oxylanthanum carbonate, a treatment for hyperphosphatemia in chronic kidney disease patients on dialysis.

Patrick Industries (NASDAQ:PATK) and LCI Industries (NYSE:LCII) have entered into a definitive agreement to combine in an all-stock merger.

GreenTree Hospitality (NYSE:GHG) reported first quarter 2026 total revenues of RMB227.7 million, equivalent to US$33 million, a decrease of 14% year over year.

AC Immune (NASDAQ:ACIU) reported 12-month interim data from the Phase 1b/2 ABATE trial of ACI-24 in 74 patients with prodromal Alzheimer’s disease across cohorts AD1-AD3.

HeartBeam (NASDAQ:BEAT) announced completion of patient enrollment in its ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack detection.

Pasithea Therapeutics (NASDAQ:KTTA) reported positive interim Phase 1 clinical trial results for PAS-004, an oral MEK inhibitor being tested in advanced MAPK pathway-driven solid tumors, including patients previously treated with MEK and BRAF inhibitors.